Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for PGEN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 38.21M
March 31, 2026 56.25M
December 31, 2025 97.86M
September 30, 2025 121.14M
June 30, 2025 59.75M
March 31, 2025 80.24M
December 31, 2024 97.91M
September 30, 2024 28.63M
June 30, 2024 19.54M
March 31, 2024 44.76M
December 31, 2023 62.86M
September 30, 2023 73.76M
June 30, 2023 88.43M
March 31, 2023 117.89M
December 31, 2022 99.29M
September 30, 2022 153.77M
June 30, 2022 115.30M
March 31, 2022 112.14M
December 31, 2021 108.66M
September 30, 2021 114.41M
June 30, 2021 115.11M
March 31, 2021 105.69M
December 31, 2020 100.12M
September 30, 2020 113.10M
June 30, 2020 133.00M
Date Value
March 31, 2020 149.17M
December 31, 2019 75.05M
September 30, 2019 106.03M
June 30, 2019 125.80M
March 31, 2019 181.82M
December 31, 2018 223.86M
September 30, 2018 254.28M
June 30, 2018 88.12M
March 31, 2018 130.49M
December 31, 2017 86.66M
September 30, 2017 115.70M
June 30, 2017 164.15M
March 31, 2017 212.22M
December 31, 2016 244.20M
September 30, 2016 243.53M
June 30, 2016 270.75M
March 31, 2016 260.39M
December 31, 2015 238.31M
September 30, 2015 216.30M
June 30, 2015 166.33M
March 31, 2015 181.48M
December 31, 2014 115.96M
September 30, 2014 123.08M
June 30, 2014 175.55M
March 31, 2014 222.81M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Geron Corp. 302.74M
Neurocrine Biosciences, Inc. 389.80M
Elicio Therapeutics, Inc. 23.48M
Agenus, Inc. 18.74M
Amgen, Inc. 13.99B